fbpx

Safilo and Jimmy Choo extend agreement

Safilo and Jimmy Choo have extended their licensing agreement until December 31, 2018.

The agreement involves the design, production, and distribution of the Jimmy Choo eyewear collections of sunglasses and optical frames. Safilo says that, after having experienced an outstanding growth across Europe and North America, the Jimmy Choo collections show great potential for similar growth in Asia Pacific, China, and Latin America.

Signed in 2007, the current agreement will end in 2015. Safilo launched its first Jimmy Choo sunglass collection in January 2008, which was soon followed by an optical frame collection. In 2011, Jimmy Choo was acquired by private equity investor JAB Holdings.

For further information: http://investors-en.safilo.com/phoenix.zhtml?c=195673&p=irol-newsArticle&ID=1993341

Featured Posts

EssilorLuxottica Oakley Enigma Ink and Enigma Mass eyewear models

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass, two lifestyle frames that redefine prescription and inspire wearers to express a whole other side of themselves.

Learn More
MIDO 2025

MIDO 2025: The 3-Day International Eyewear Show Concludes in Milan

More than 42,000 attendees from 168 countries, and 1,200 exhibitors, of those about 930 international, in 8 exhibit areas across 7 pavilions.

Read more
Voila Optik Jan-Feb 2025 WestGroupe Moleskine MO1263

A Fusion of Design and Eco-Conscious Practices with Moleskine Eyewear

MO-1263 in Tortoise Blue features a very classic tortoise pattern with blue temples.

Read more
Rolf CSE Award winner at Mido 2025

Rolf Wins CSE Award 2025

Austrian eyewear manufacturer Rolf received a prestigious award: the company has been honoured with the renowned CSE (Certified Sustainable Eyewear) Award for the second time in a row.

Read more
Fighting Blindness Canada

Phase 1 Study Finds Bone Marrow Stem Cells Safe as Potential Treatment for Retinitis Pigmentosa

A team of researchers at University of California Davis has published the results of a Phase 1 clinical trial testing stem cells therapy for retinitis pigmentosa (RP).

Read more
EssilorLuxottica Oakley Enigma Ink and Enigma Mass eyewear models

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass, two lifestyle frames that redefine prescription and inspire wearers to express a whole other side of themselves.

Learn More
MIDO 2025

MIDO 2025: The 3-Day International Eyewear Show Concludes in Milan

More than 42,000 attendees from 168 countries, and 1,200 exhibitors, of those about 930 international, in 8 exhibit areas across 7 pavilions.

Read More
Voila Optik Jan-Feb 2025 WestGroupe Moleskine MO1263

A Fusion of Design and Eco-Conscious Practices with Moleskine Eyewear

MO-1263 in Tortoise Blue features a very classic tortoise pattern with blue temples.

Read More
Rolf CSE Award winner at Mido 2025

Rolf Wins CSE Award 2025

Austrian eyewear manufacturer Rolf received a prestigious award: the company has been honoured with the renowned CSE (Certified Sustainable Eyewear) Award for the second time in a row.

Read More
Fighting Blindness Canada

Phase 1 Study Finds Bone Marrow Stem Cells Safe as Potential Treatment for Retinitis Pigmentosa

A team of researchers at University of California Davis has published the results of a Phase 1 clinical trial testing stem cells therapy for retinitis pigmentosa (RP).

Read More
EssilorLuxottica Oakley Enigma Ink and Enigma Mass eyewear models

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass, two lifestyle frames that redefine prescription and inspire wearers to express a whole other side of themselves.

Learn More
MIDO 2025

MIDO 2025: The 3-Day International Eyewear Show Concludes in Milan

More than 42,000 attendees from 168 countries, and 1,200 exhibitors, of those about 930 international, in 8 exhibit areas across 7 pavilions.

Read more
Voila Optik Jan-Feb 2025 WestGroupe Moleskine MO1263

A Fusion of Design and Eco-Conscious Practices with Moleskine Eyewear

MO-1263 in Tortoise Blue features a very classic tortoise pattern with blue temples.

Read more
Rolf CSE Award winner at Mido 2025

Rolf Wins CSE Award 2025

Austrian eyewear manufacturer Rolf received a prestigious award: the company has been honoured with the renowned CSE (Certified Sustainable Eyewear) Award for the second time in a row.

Read more
Fighting Blindness Canada

Phase 1 Study Finds Bone Marrow Stem Cells Safe as Potential Treatment for Retinitis Pigmentosa

A team of researchers at University of California Davis has published the results of a Phase 1 clinical trial testing stem cells therapy for retinitis pigmentosa (RP).

Read more
EssilorLuxottica Oakley Enigma Ink and Enigma Mass eyewear models

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass

Oakley® Authentic Prescription unravels the mystery with Enigma Ink and Enigma Mass, two lifestyle frames that redefine prescription and inspire wearers to express a whole other side of themselves.

Learn More
MIDO 2025

MIDO 2025: The 3-Day International Eyewear Show Concludes in Milan

More than 42,000 attendees from 168 countries, and 1,200 exhibitors, of those about 930 international, in 8 exhibit areas across 7 pavilions.

Read more
Voila Optik Jan-Feb 2025 WestGroupe Moleskine MO1263

A Fusion of Design and Eco-Conscious Practices with Moleskine Eyewear

MO-1263 in Tortoise Blue features a very classic tortoise pattern with blue temples.

Read more
Rolf CSE Award winner at Mido 2025

Rolf Wins CSE Award 2025

Austrian eyewear manufacturer Rolf received a prestigious award: the company has been honoured with the renowned CSE (Certified Sustainable Eyewear) Award for the second time in a row.

Read more
Fighting Blindness Canada

Phase 1 Study Finds Bone Marrow Stem Cells Safe as Potential Treatment for Retinitis Pigmentosa

A team of researchers at University of California Davis has published the results of a Phase 1 clinical trial testing stem cells therapy for retinitis pigmentosa (RP).

Read more